Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D'Angelo, J Russell, C Lebbé, B Chmielowski… - JAMA …, 2018 - jamanetwork.com
Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated
with poor survival outcomes in patients with distant metastatic disease. Results of part A of
the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that
avelumab, an anti–programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy
in second-line or later treatment of patients with metastatic MCC (mMCC). Objective To
evaluate the efficacy and safety of avelumab as first-line treatment for patients with distant …
with poor survival outcomes in patients with distant metastatic disease. Results of part A of
the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that
avelumab, an anti–programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy
in second-line or later treatment of patients with metastatic MCC (mMCC). Objective To
evaluate the efficacy and safety of avelumab as first-line treatment for patients with distant …